Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes in the United Kingdom
about
Costs and consequences associated with newer medications for glycemic control in type 2 diabetes.Cost-utility analysis of glucagon-like Peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn Basal insulin as add-on to metformin in type 2 diabetes in swedenGlucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials.Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study.Incretin-based therapies: new treatments for type 2 diabetes in the new millennium.Type 2 diabetes family histories, body composition and fasting glucose levels: a cross-section analysis in healthy sedentary male and female.Managing type 2 diabetes: new policy and interventions.Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom.Inclusion of compliance and persistence in economic models: past, present and future.Review of models used in economic analyses of new oral treatments for type 2 diabetes mellitus.Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus.Utility estimates for patients with Type 2 diabetes mellitus after experiencing a myocardial infarction or stroke: a systematic review.Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands.Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus.Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes.Understanding GLP-1 analogs and enhancing patients success.
P2860
Q33751401-3C85A035-04CB-455B-BEFF-E123DB5EC055Q34726534-D390406E-96B6-4A65-9BE2-EB4F99E8F10AQ35136457-184D7F71-5D4C-4C94-8313-8EABEA875A21Q37087031-3D4B8DAC-2004-4E19-9EE9-44B2731825BBQ37316259-085DB0A8-969A-4065-BF9D-B3B2040F87E4Q37436883-D5879E7B-C5FA-40BC-8049-484A1FEA077FQ37549855-87B4710A-F6CE-4C9F-8613-BFF1D4ED71A9Q37639302-45CEE628-F59D-454F-96E5-87B45688F7CFQ38048913-0163AA22-96B9-4F2D-978A-FD6BB717C702Q38172859-3BD208B4-B6F3-4A90-9253-1B221A232B43Q38179267-6B32E1BF-3365-4749-9B21-6D0AF212BD86Q38306101-D818FA1F-7AC0-49B5-B10A-3BD92199BE49Q38441105-F95A0AB3-A49B-4C2C-A293-126A067EB410Q38815279-D795798B-5FC7-4911-AF10-91891315DA12Q38983622-DCB46ECA-8551-4FF0-9F20-51013FCE0BF4Q42660412-2F6AD7A3-EFE7-4862-A78B-436C40372468Q42927083-48A2DBD9-D552-40A6-A992-4EEB46CE07B9
P2860
Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes in the United Kingdom
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Evaluation of the cost effecti ...... diabetes in the United Kingdom
@en
type
label
Evaluation of the cost effecti ...... diabetes in the United Kingdom
@en
prefLabel
Evaluation of the cost effecti ...... diabetes in the United Kingdom
@en
P2093
P2860
P356
P1476
Evaluation of the cost effecti ...... diabetes in the United Kingdom
@en
P2093
Anette Woehl
Anthony P Tetlow
Philip McEwan
P2860
P2888
P356
10.1186/1475-2840-7-24
P407
P577
2008-08-11T00:00:00Z
P5875
P6179
1052715065